<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Oncolytic adenoviruses are a promising treatment alternative for many <z:e sem="disease" ids="C0877373" disease_type="Neoplastic Process" abbrv="">advanced cancers</z:e>, including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, clinical trials have demonstrated that single-agent therapy in advanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> masses is rarely curative </plain></SENT>
<SENT sid="2" pm="."><plain>Poor spreading of the virus through <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue is one of the major issues limiting efficacy </plain></SENT>
<SENT sid="3" pm="."><plain>As oncolytic viruses kill preferentially <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, high extracellular matrix (ECM) content constitutes potential barriers for <z:mp ids='MP_0001799'>viral</z:mp> penetration within <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, the ECM-degrading proteases relaxin, hyaluronidase, elastase and macrophage metalloelastase (MME) were tested for their antitumor efficacy alone and in combination with oncolytic adenovirus </plain></SENT>
<SENT sid="5" pm="."><plain>MME improved the overall antitumor efficacy of oncolytic adenovirus in subcutaneous HCT116 xenografts </plain></SENT>
<SENT sid="6" pm="."><plain>In a liver <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> model, intra-tumoral treatment of <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> from HT29 cells with MME monotherapy or with oncolytic adenovirus inhibited <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Combination therapy showed no increased mortality in comparison with either monotherapy alone </plain></SENT>
<SENT sid="8" pm="."><plain>Contradictory results of effects of MME on <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> formation have been reported in the literature </plain></SENT>
<SENT sid="9" pm="."><plain>This study demonstrates for the first time in a metastatic animal model that MME, as a monotherapy or in combination with oncolytic virus, does not increase <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> invasiveness </plain></SENT>
<SENT sid="10" pm="."><plain>Co-administration of MME and oncolytic adenovirus may be a suitable approach for further optimization aiming at clinical applications for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
</text></document>